The Europe Pharmaceuticals & Healthcare Reports feature independent forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
Benchmark independent pharmaceutical and healthcare industry forecasts to test other views - a key input for successful budgeting and strategic business planning in the pharmaceutical and healthcare market.
Target business opportunities and risks in the pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments.
Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
These reports provide industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the pharmaceutical and healthcare industry.
These Reports analyse key issues in European Markets
Europe Pharmaceuticals and Healthcare Reports are a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include 4 completely updated reports sent quarterly, together with a comprehensive statistical appendix. There are over 60 markets covered in the worldwide series.
Europe Pharmaceutical & Healthcare Reports cover…
Belarus, Belgium, Bulgaria, Croatia, Czech, Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United, Kingdom, Uzbekistan
Use these original and insightful reports to...
Assess future market values with our unique and regularly reviewed independent 5-year market forecasts.
Track the latest developments with the news service that is included for every country.
Understand the critical issues and drivers which are shaping the market.
Evaluate the environment for branded and generic operators and stay in touch with the fast growing biologic sector.
Shape and support business plans and decisions with reliable business data.
Benchmark key market performance with Espicom’s standardised data.
Download Sample copy of Report at http://www.marketresearchreports.biz/sample/sample/166284
Highlights from the Reports
Our outlook for Hungary's pharmaceutical market remains negative, given the government's policies that shift the burden of the National Healthcare Fund (OEP) onto drug manufacturers. Pricing pressure and claw-back taxes have squeezed domestic manufacturers' margins and introduced insecurity to an already difficult economic environment, and we continue to expect a contraction in the size of the Hungarian pharmaceutical market in 2012 and 2013. Consequently, Hungarian drug makers will have to become even more export orientated.
The Russian pharmaceutical market remains a powerhouse in the Emerging Europe region . The country has by far the largest population in the region. Its resources -driven economic growth is funding both private and public spending on medicines and healthcare services. The country's World Trade Organisation (WTO) accession has eliminated tariff barriers and should, in the long run, drive major improvements in a problematic intellectual property environment. Both domestic and cross-border mergers and acquisitions (M&A) activity has picked up since the 2009 economic crisis, a result of increased incentives for local production under the government's industrial policy for the sector and the need for scale to compete , especially in the generic medicines market
The cooling economic environment and the weakening lira has moderated optimistic forecasts on the Turkish pharmaceutical market, especially as the government is the single largest reimburser of pharmaceuticals, covering 80-85% of total drug expenditure through various insurance and immunisation schemes. Price cutting and public discount decrees announced in November 2011 continue to affect the pharmaceutical market in 2012, as highlighted by the decrease in pharmaceutical spending in the first half of this year.